| The North American Fragmin Trial (NAFT) studied dalteparin (Fragmin ®) in the prevention of venous thromboembolism (VTE) after total hip replacement. This subject is worthy of continuing research because symptomatic VTE continues to occur in 2-3% of patients despite current prophylaxis with either warfarin or low molecular weight heparin (LMWH). Even more patients develop asymptomatic deep venous thrombosis (DVT), which can lead to chronic deep venous insufficiency commonly called the post thrombotic syndrome. |
